Yoshimasa Hoshikawa Selected Research

Peptic Esophagitis (Reflux Esophagitis)

1/2024	Characteristics of proton pump inhibitor-resistant severe reflux esophagitis and efficacy of vonoprazan in elderly (older than 75 years) and non-elderly groups.
1/2023	Differences in salivary secretion and epidermal growth factor concentrations in mild reflux esophagitis and non-erosive reflux disease.
1/2023	Saliva Secretion Is Significantly Lower in Female Patients with Mild Reflux Esophagitis than in Female Healthy Controls.
1/2023	Proton Pump Inhibitor Treatment Has Little Effects on Secretion of Saliva in Patients with Proton Pump Inhibitor-Responsive Mild Reflux Esophagitis and Non-Erosive Reflux Disease.
1/2022	Saliva secretion is reduced in mild reflux esophagitis patients.
1/2021	Relationship between gastroesophageal reflux disease (GERD) and constipation: laxative use is common in GERD patients.
1/2021	Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients.
1/2020	Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis.
10/2019	Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
1/2018	Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshimasa Hoshikawa Research Topics

Disease

11	Peptic Esophagitis (Reflux Esophagitis) 01/2024 - 01/2017
9	Non-Erosive Reflux Disease 01/2023 - 01/2017
6	Gastroesophageal Reflux (GERD) 01/2023 - 06/2018
4	Heartburn (Pyrosis) 01/2023 - 01/2020
2	Hemorrhage 01/2024 - 01/2020
2	Pathologic Constriction (Stenosis) 01/2024 - 01/2020
2	Esophageal Achalasia (Megaesophagus) 10/2023 - 08/2023
2	Hypersensitivity (Allergy) 01/2023 - 01/2021
2	Infections 01/2020 - 01/2017
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2023
1	Dyspepsia (Indigestion) 03/2022
1	Rumination Syndrome (Rumination Disorder) 01/2021
1	Constipation 01/2021
1	Eructation (Eructations) 01/2021
1	Hiatal Hernia 01/2020
1	Atrophy 01/2020
1	Kyphosis 01/2020

Drug/Important Bio-Agent (IBA)

11	Proton Pump InhibitorsIBA 01/2024 - 01/2017
10	AcidsIBA 01/2023 - 01/2017
7	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamineIBA 01/2024 - 01/2017
3	Epidermal Growth Factor (EGF)IBA 01/2023 - 01/2021
3	PotassiumIBA 01/2022 - 01/2017
1	Botulinum Toxins (Botulinum Toxin)IBA 08/2023
1	lemborexantIBA 01/2023
1	Hypnotics and Sedatives (Sedatives)IBA 01/2023
1	liu-jun-zi-tangIBA 03/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 03/2022
1	LaxativesIBA 01/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2020
1	beta-Aminoethyl Isothiourea (AET)IBA 01/2020
1	GastrinsIBA 10/2019
1	TabletsIBA 01/2019

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2018
1	Catheters 10/2023
1	Injections 08/2023
1	Myotomy 08/2023